Video
Dr. Spigel on CheckMate-331 Trial for SCLC
Author(s):
David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.
David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.
The open-label, international, randomized phase III trial, which is exploring the role of nivolumab versus topotecan, is currently enrolling patients. The primary endpoint, Spigel adds, is overall survival.
Researchers are hopeful that the immunotherapy agent will show a survival benefit when compared with topotecan, as well as demonstrate a more favorable safety profile.
